Youram Nassir

644 total citations
39 papers, 490 citations indexed

About

Youram Nassir is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Youram Nassir has authored 39 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Youram Nassir's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (11 papers). Youram Nassir is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (16 papers) and Peptidase Inhibition and Analysis (11 papers). Youram Nassir collaborates with scholars based in United States and Mexico. Youram Nassir's co-authors include James R. Berenson, Regina A. Swift, Ori Yellin, Robert Vescio, Ralph V. Boccia, James Hilger, Marshall S. Flam, Alberto Bessudo, Shahrooz Eshaghian and Dipti Patel‐Donnelly and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Youram Nassir

38 papers receiving 484 citations

Peers

Countries citing papers authored by Youram Nassir

Since Specialization

Citations

This map shows the geographic impact of Youram Nassir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youram Nassir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youram Nassir more than expected).

Fields of papers citing papers by Youram Nassir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youram Nassir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youram Nassir. The network helps show where Youram Nassir may publish in the future.

Co-authorship network of co-authors of Youram Nassir

This figure shows the co-authorship network connecting the top 25 collaborators of Youram Nassir. A scholar is included among the top collaborators of Youram Nassir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youram Nassir. Youram Nassir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment 2017 ·Supportive Care in Cancer ·(unknown), James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky, Imad A. Tabbara, (unknown), Sikander Ailawadhi, Laura Stampleman, Ronald G. Steis, Mehdi M. Moezi, Regina A. Swift, (unknown), Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, James R. Berenson	2
2	Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib 2016 ·Annals of Hematology ·(unknown), Suzie Vardanyan, (unknown), James Wang, Nika M Harutyunyan, (unknown), (unknown), Tanya M. Spektor, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, (unknown), Regina A. Swift, James R. Berenson	14
3	Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic 2016 ·Annals of Hematology ·(unknown), Suzie Vardanyan, (unknown), James Wang, Nika M Harutyunyan, (unknown), (unknown), Tanya M. Spektor, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, (unknown), Regina A. Swift, James R. Berenson	6
4	Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM). 2015 ·Journal of Clinical Oncology ·James R. Berenson, Laura Stampleman, Alberto Bessudo, Peter J. Rosen, Leonard M. Klein, Thomas Woliver, Marshall S. Flam, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	2
5	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy 2014 ·Leukemia ·James R. Berenson, James Hilger, Ori Yellin, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	55
6	A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma 2014 ·Supportive Care in Cancer ·James R. Berenson, Ori Yellin, (unknown), Chien-Shing Chen, Veena Charu, Thomas Woliver, (unknown), (unknown), Youram Nassir, Regina A. Swift, Claudia Andreu‐Vieyra, Robert Vescio	27
7	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma 2013 ·Annals of Hematology ·James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, (unknown), Hassan Ghazal, (unknown), Edwin Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert Vescio	34
8	A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM). 2013 ·Journal of Clinical Oncology ·James Hilger, James R. Berenson, Leonard M. Klein, Alberto Bessudo, Peter J. Rosen, Shahrooz Eshaghian, (unknown), Youram Nassir, Regina A. Swift, Robert Vescio	3
9	A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma 2012 ·Leukemia ·(unknown), Ori Yellin, (unknown), (unknown), Chen‐Li Cheng, Alan Cartmell, Thomas Woliver, Marshall S. Flam, (unknown), Youram Nassir, Robert Vescio, (unknown)	32
10	A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen. 2012 ·Journal of Clinical Oncology ·James R. Berenson, Ori Yellin, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, James Hilger, Youram Nassir, Regina A. Swift, Robert Vescio	5
11	Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma 2012 ·British Journal of Haematology ·James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald Gravenor, Dipti Patel‐Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Youram Nassir, Regina A. Swift, (unknown)	39
12	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients 2011 ·British Journal of Haematology ·James R. Berenson, Ori Yellin, (unknown), Ravi Patel, Alberto Bessudo, Ralph V. Boccia, Hank H. Yang, Robert Vescio, Elizabeth Yung, Russell Mapes, (unknown), James Hilger, (unknown), (unknown), Youram Nassir, Regina A. Swift	25
13	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid 2010 ·American Journal of Hematology ·James R. Berenson, Ori Yellin, John Crowley, Adel Makary, Donald Gravenor, Hank H. Yang, (unknown), Ian W. Flinn, Harry Staszewski, (unknown), (unknown), Charles M. Farber, Neil Morganstein, Vanessa Bolejack, Youram Nassir, James Hilger, (unknown), (unknown), Regina A. Swift	15
14	A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM) 2010 ·Blood ·James R. Berenson, Ori Yellin, Alan Cartmell, Thomas Woliver, Marshall S. Flam, Youram Nassir, Robert Vescio, Regina A. Swift	2
15	Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen 2009 ·European Journal Of Haematology ·James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, (unknown), Youram Nassir, (unknown), (unknown), (unknown), Regina A. Swift	21
16	A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma 2009 ·Clinical Cancer Research ·James R. Berenson, Ori Yellin, Ravi Patel, (unknown), Youram Nassir, Russell Mapes, (unknown), Regina A. Swift	29
17	A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM). 2009 ·Blood ·James R. Berenson, Ori Yellin, Ravi Patel, Chien-Shing Chen, Ralph V. Boccia, (unknown), (unknown), (unknown), George F. Geils, Youram Nassir, (unknown), Regina A. Swift	1
18	Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up 2008 ·Annals of Hematology ·James R. Berenson, Hank H. Yang, Robert Vescio, Youram Nassir, Russell Mapes, (unknown), (unknown), Ori Yellin, Blake Morrison, (unknown), Regina A. Swift	31
19	Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen. 2007 ·Blood ·James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, (unknown), Youram Nassir, Regina A. Swift	8
20	Expression of I2-imidazoline sites in rat prostate 1996 ·Biochemical Pharmacology ·Soundararajan Regunathan, Youram Nassir, K. Sundaram, E. Darracott Vaughan, D J Reis, Diane Felsen	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact